Posted by Michael Wonder on 28 Feb 2024
Incyte announces US FDA grants priority review for axatilimab for the treatment of chronic graft versus host disease
27 February 2024 - Priority review acceptance based on positive results of AGAVE-201 study.
Incyte today announced that the US FDA has accepted for priority review the biologics license application for axatilimab, an anti-CSF-1R antibody, for the treatment of chronic graft versus host disease after failure of at least two prior lines of systemic therapy.
